



STEVEN L. JACKSON  
DAVID A. JACKSON  
STEVE S. CHA  
VALETA A. GREGG, PH.D.\*  
STEPHEN GIGANTE  
LAWRENCE D. MANDEL\*  
CATHERINE ROSEMAN SMITH\*  
JAMES E. PITTMAN

\*BAR OTHER THAN N.J.  
\*COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.  
MICHAEL A. YAMIN, PH.D.

SCIENTIFIC ADVISOR

VERONICA M. MALLON, PH.D.

**COPY**

**KLAUBER & JACKSON**  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND  
COPYRIGHT CAUSES

(201) 487-5800

FACSIMILE: (201) 343-1684

WWW.KJIPLAW.COM

WRITER'S E-MAIL:

DAVID.JACKSON@KJIPLAW.COM

September 20, 2002

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

Re: U.S. Patent Application

Applicant(s): Moses Rodriguez et al.

Title: HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND  
THERAPEUTIC USES THEREOF PARTICULARLY IN  
THE CENTRAL NERVOUS SYSTEM

Serial No.: 10/010,729

Filed: November 13, 2001

Docket No.: 1199-1-005CIP2

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231 on September 20, 2002.

David A. Jackson, Reg. No. 26,742  
(Name of Registered Representative)

Martha Bussanich 9/20/02  
(Signature and Date)

**SUBMISSION OF SEQUENCE LISTING**

Sir:

Responsive to the Notice dated March 20, 2002, and in accordance with 37 CFR 1.821-1.825, Applicants submit herewith the following:

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.


2. A copy of the Sequence Listing in computer readable form (ASCII text), submitted on a 3½" floppy disk compatible with IBM format.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
4. A copy of the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The time set for this response is September 20, 2002.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,



David A. Jackson  
Attorney for Applicant(s)  
Registration No. 26,742

DAJ/mb  
Enclosures

KLAUBER & JACKSON